Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect

BMC Complementary and Alternative Medicine

Volumn 12, Issue , 2012, Pages

  Ogawa, Kazuo ^a   Omatsu, Tatsushi ^b   Matsumoto, Chinami ^a   Tsuchiya, Naoko ^a   Yamamoto, Masahiro ^a   Naito, Yuji ^b   Yoshikawa, Toshikazu ^b  

^a Tsumura Research Laboratories   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Albumin fragment; Bone marrow suppression; Juzentaihoto; SELDI TOF MS; TS 1

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; JUZENTAIHOTO; PLANT MEDICINAL PRODUCT; PROTEIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; BONE MARROW SUPPRESSION; CARBOXY TERMINAL SEQUENCE; CATION EXCHANGE; CD34 SELECTION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME METABOLISM; FEMALE; FLOW CYTOMETRY; ION EXCHANGE CHROMATOGRAPHY; JAPANESE; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MEDICINAL PLANT; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; PURIFICATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TRADITIONAL MEDICINE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BONE MARROW; DRUGS, CHINESE HERBAL; FEMALE; HEMATOPOIESIS; HUMANS; JAPAN; LEUKOPENIA; MASS SPECTROMETRY; MEDICINE, KAMPO; MICE; MICE, INBRED BALB C; PROTECTIVE AGENTS; PROTEOMICS; TEGAFUR;

EID: 84864661584     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-12-118     Document Type: Article

References (41)

1. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557. 10.1097/00001813-199607000-00010, 8862723.
2. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M. Antitumor Activity of 1M Tegafur-0.4M 5-Chloro-2,4-dihydroxypyridine-1M potassium Oxonate (S-1) against Human Colon Carcinoma Orthotopically Implanted into Nude Rats. Cancer Res 1996, 56:2602-2606.
3. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. J Clin Oncol 2009, 39:2-15.
4. Saiki I. A Kampo medicine " Juzen-taiho-to" -Prevention of malignant Progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull 2000, 23:677-688. 10.1248/bpb.23.677, 10864015.
5. Hisha H, Yamada H, Sakurai MH, Kiyohara H, Li Y, Yu C, Takemoto N, Kawamura H, Yamaura K, Shinohara S, Komatsu Y, Aburada M, Ikehara S. Isolation and identification of hematopoietic stem cell-stimulating substances from Kampo (Japanese herbal) medicine, Juzen-taiho-to. Blood 1997, 90:1022-1030.
6. Sugiyama K, Ueda H, Ichio Y, Yokota M. Improvement of cisplatin toxicity and lethality by Juzen-taiho-to in mice. Biol Pharm Bull 1995, 18:53-58. 10.1248/bpb.18.53, 7735251.
7. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577. 10.1016/S0140-6736(02)07746-2, 11867112.
8. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003, 3:2310-2316. 10.1002/pmic.200300590, 14673781.
9. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002, 48:1835-1843.
10. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003, 63:6971-6983.
11. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI. Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 2003, 361:1258-1265. 10.1016/S0140-6736(03)12981-9, 12699953.
12. Tomosugi N. Discovery of disease biomarkers by ProteinChip system; clinical proteomics as noninvasive diagnostic tool. Rinsho Byori 2004, 52:973-979.
13. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993, 53:4004-4009.
14. Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T. Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000, 18:315-329. 10.1023/A:1006476730671, 11081568.
15. Ogawa K, Kojima T, Matsumoto C, Kamegai S, Oyama T, Shibagaki Y, Muramoto H, Kawasaki T, Fujinaga H, Takahashi K, Hikiami H, Goto H, Kiga C, Koizumi K, Sakurai H, Shimada Y, Yamamoto M, Terasawa K, Takeda S, Saiki I. Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin Biochem 2007, 40:1113-1121. 10.1016/j.clinbiochem.2007.06.005, 17673196.
16. Matsumoto C, Kojima T, Ogawa K, Kamegai S, Oyama T, Shibagaki Y, Kawasaki T, Fujinaga H, Takahashi K, Hikiami H, Goto H, Kiga C, Koizumi K, Sakurai H, Muramoto H, Shimada Y, Yamamoto M, Terasawa K, Takeda S, Saiki I. A proteomic approach for the diagnosis of 'Oketsu' (blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine. Evid Based Complement Alternat Med 2008, 5:463-474. 10.1093/ecam/nem049, 2586309, 18955217.
17. Marcus R, Eric P, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976, 63:655-660.
18. Kawamura H, Maruyama H, Takemoto N, Komatsu Y, Aburada M, Ikehara S, Hosoya E. Accelerating effect of Japanese Kampo medicine on Recovery of murine haematopoietic stem cells after administration of mitomycin C. Int J Immunotherapy 1989, 5:35-42.
19. Maruyama H, Takemoto N, Maruyama N, Komatsu Y, Kawamura H. Antitumour effect of juzentaiho-to, a Kampo medicime, combined with surgical excision for transplanted Meth-A fibrosarcoma. Int J Immunotherapy 1993, 9:117-125.
20. Ohnishi Y, Yasumizu R, Fan HX, Liu J, Takao-Liu F, Komatsu Y, Hosoya E, Good RA, Ikehara S. Effect of juzen-taiho-toh (TJ-48), a traditional oriental medicine, on hematopoietic recovery from radiation injury in mice. Exp Hematol 1990, 18:18-22.
21. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL™) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000, 18:331-342. 10.1023/A:1006445214741, 11081569.
22. Nabeya K, Ri S. Effect of oriental medical herbs on the restoration of the human body before and after operation. Pro. Symp WAKAN-YAKU 1983, 16:201-206.
23. Terasawa K, Shimada Y, Kita T, Yamamoto T, Tosa H, Tanaka N, Saito Y, kanaki E, Goto S, Mizusima N, Fujioka M, Takase S, Seki H, Kimura I, Ogawa T, Nakamura S, Araki G, Maruyama I, Maruyama Y, Takaori S. Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine 1997, 4:15-22.
24. Miyamoto T, Inoue H, Kitamura S, Yamamoto M, Yamakido M, Nagano H, Egashira Y, Nakashima M. Effect of TSUMURA Sho-seiryu-to (TJ-19) on bronchitis in a double-blind placebo-controlled Study. J Clin Ther Med 2001, 17:1189-1214.
25. Kiga C, Nakagawa T, Koizumi K, Sakurai H, Shibagaki Y, Ogawa K, Goto H, Saiki I. Expression patterns of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform. Biol Pharm Bull 2005, 28:1031-1037. 10.1248/bpb.28.1031, 15930740.
26. Grochow LB, Noe DA, Effinger DS, Donehower RC. A phase I trial of trimetrexate (NSC 352122) given every 3 week: clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol 1989, 24:314-320. 10.1007/BF00304765, 2758561.
27. Kimura M, Morihata K, Ito D, Iwai M, Okada K, Usami E, Nakao T, Yoshimura T, Yasuda T. Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer. Gan To Kagaku Ryoho 2010, 37:829-834.
28. Mick R, Ratain MJ. Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991, 83:1560-1564. 10.1093/jnci/83.21.1560, 1960753.
29. Kaul S, Srinivas NR, Igwemezie LN, Barbhaiya RH. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. Semin Oncol 1996, 23(Suppl 13):15-22.
30. Arakawa A, Nishikawa H, Suzumori K, Kato N. Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. Int J Clin Oncol 2001, 6:248-252. 10.1007/PL00012113, 11723747.
31. Heissig B, Lund LR, Akiyama H, Ohki M, Morita Y, Rømer J, Nakauchi H, Okumura K, Ogawa H, Werb Z, Danø K, Hattori K. The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell 2007, 1:658-670. 10.1016/j.stem.2007.10.012, 2646407, 18371407.
32. Heissig B, Ohki M, Ishihara M, Tashiro Y, Nishida C, Gritli I, Rosenkvist J, Hattori K. Contribution of the fibrinolytic pathway to hematopoietic regeneration. J Cell Physiol 2009, 221:521-525. 10.1002/jcp.21897, 19681053.
33. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009, 19:471-477. 10.1016/j.ghir.2009.03.001, 2787983, 19386527.
34. Vento G, Tirone C, Lulli P, Capoluongo E, Ameglio F, Lozzi S, Cota F, Mosca F, Romagnoli C, Messana I, Castagnola M, Inzitari R. Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia. Intensive Care Med 2009, 35:2115-2124. 10.1007/s00134-009-1646-6, 19779697.
35. Hellin JL, Bech-Serra JJ, Moctezuma EL, Chocron S, Santin S, Madrid A, Vilalta R, Canals F, Torra R, Meseguer A, Nieto JL. Very low-molecular-mass Fragments of Albumin in the plasma of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 2009, 54:871-880. 10.1053/j.ajkd.2009.07.011, 19781833.
36. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:43-51. 10.1038/ncpgasthep0680, 17203088.
37. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000, 85:599-610. 10.1093/bja/85.4.599, 11064620.
38. Avidan B. The use of albumin in all patients with decompensated cirrhosis is not justified. Isr Med Assoc J 2005, 7:118-120.
39. Rena NM, Wibawa ID. Albumin infusion in liver cirrhotic patients. Acta Med Indones 2010, 42:162-168.
40. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94:1898-1905. 10.1038/sj.bjc.6603188, 2361335, 16755300.
41. Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, Ward BJ. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010, 48:1139-1149. 10.1128/JCM.02207-09, 2849606, 20071547.